Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.

Wang J, Yang DH, Yang Y, Wang JQ, Cai CY, Lei ZN, Teng QX, Wu ZX, Zhao L, Chen ZS.

Int J Mol Sci. 2020 Feb 19;21(4). pii: E1387. doi: 10.3390/ijms21041387.

2.

Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.

Wei LY, Wu ZX, Yang Y, Zhao M, Ma XY, Li JS, Yang DH, Chen ZS, Fan YF.

Exp Cell Res. 2020 Jan 20:111858. doi: 10.1016/j.yexcr.2020.111858. [Epub ahead of print]

PMID:
31972220
3.

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.

Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186.

4.

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study.

Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D.

Front Oncol. 2019 Jun 18;9:514. doi: 10.3389/fonc.2019.00514. eCollection 2019.

5.

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Wu ZX, Teng QX, Cai CY, Wang JQ, Lei ZN, Yang Y, Fan YF, Zhang JY, Li J, Chen ZS.

Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9.

PMID:
31078601

Supplemental Content

Loading ...
Support Center